S

Shionogi & Co Ltd
TSE:4507

Watchlist Manager
Shionogi & Co Ltd
TSE:4507
Watchlist
Price: 2 125.5 JPY -0.86%
Market Cap: 1.8T JPY
Have any thoughts about
Shionogi & Co Ltd?
Write Note

Shionogi & Co Ltd
Income to Minority Interest

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shionogi & Co Ltd
Income to Minority Interest Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income to Minority Interest CAGR 3Y CAGR 5Y CAGR 10Y
S
Shionogi & Co Ltd
TSE:4507
Income to Minority Interest
ÂĄ1.3B
CAGR 3-Years
N/A
CAGR 5-Years
38%
CAGR 10-Years
N/A
Takeda Pharmaceutical Co Ltd
TSE:4502
Income to Minority Interest
-ÂĄ173m
CAGR 3-Years
5%
CAGR 5-Years
-1%
CAGR 10-Years
24%
Daiichi Sankyo Co Ltd
TSE:4568
Income to Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Otsuka Holdings Co Ltd
TSE:4578
Income to Minority Interest
-ÂĄ3.6B
CAGR 3-Years
5%
CAGR 5-Years
1%
CAGR 10-Years
-10%
Chugai Pharmaceutical Co Ltd
TSE:4519
Income to Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Astellas Pharma Inc
TSE:4503
Income to Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shionogi & Co Ltd
Glance View

Market Cap
1.8T JPY
Industry
Pharmaceuticals

Shionogi & Co. Ltd., a prominent Japanese pharmaceutical company founded in 1878, has established itself as a key player in the global healthcare landscape through its unwavering commitment to innovation and patient-centric solutions. With a rich history that spans over a century, Shionogi has evolved from its roots in traditional medicine to a forward-thinking biopharmaceutical enterprise. It focuses on developing treatments for infectious diseases, pain management, and central nervous system disorders, leveraging its cutting-edge research capabilities and extensive pipeline of drugs. The company's strategic emphasis on transformative therapies not only aims to tackle prevalent health issues but also positions Shionogi for sustainable long-term growth in a competitive market. For investors, Shionogi offers a compelling story marked by strong fundamentals and a robust pipeline. As the company continues to target unmet medical needs, its recent advancements in antiviral treatments, particularly against COVID-19, demonstrate its agility in responding to global health crises. With a solid balance sheet and a history of steady revenue growth, Shionogi is well-equipped to navigate the evolving pharmaceutical landscape. Moreover, the company's commitment to research and development, which accounts for a significant portion of its budget, signals a proactive approach toward future innovations. For those looking to invest in a company with a legacy of excellence and a forward-looking vision, Shionogi & Co. Ltd. represents an enticing opportunity that combines stability with the promise of growth.

Intrinsic Value
2 182.84 JPY
Undervaluation 3%
Intrinsic Value
Price
S

See Also

What is Shionogi & Co Ltd's Income to Minority Interest?
Income to Minority Interest
1.3B JPY

Based on the financial report for Sep 30, 2024, Shionogi & Co Ltd's Income to Minority Interest amounts to 1.3B JPY.

What is Shionogi & Co Ltd's Income to Minority Interest growth rate?
Income to Minority Interest CAGR 5Y
38%

Over the last year, the Income to Minority Interest growth was 31%.

Back to Top